1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited

PAR.NS
Par Drugs and Chemicals LimitedIN flagNational Stock Exchange of India
92.50
INR
+2.01
- -
1.14BMarket Cap
Par Drugs and Chemicals Limited
PAR.NS
(National Stock Exchange of India)

Recent

price

92.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
37.97
34.16
37.04
44.78
48.66
60.3
77.28
77.29
82.09
- -
84.12
Revenue per Share
1.5
1.22
2.04
3.87
9.44
7.49
9.21
11.78
10.86
- -
10.64
Basic EPS, GAAP
5.98
2.99
2.45
4.98
5.72
3.59
4.67
11.51
12.14
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.63
0.62
1.25
- -
- -
- -
- -
- -
Dividend per Share
10.85
12.06
15.41
19.25
28.68
39.9
49.14
60.84
71.71
- -
9.99
Book Value per Share
10.93
12.15
23.59
33.01
42.43
48.66
57.9
69.59
80.47
- -
90.88
Tangible Book Value per Share
12
12
12
12
12
12
12
12
12
- -
12
Basic Weighted Avg Shares
467
420
456
551
599
742
951
951
1,010
1,037
1,037
Sales/Revenue/Turnover
12.07
11.53
11.36
11.71
21.98
17.06
15.31
21.2
15.7
12.95
12.95
Operating Margin (%)
28
31
30
28
28
33
32
34
36
37
37
Depreciation Expense
18
15
25
48
116
92
113
145
134
131
131
Net Income, GAAP
41.95
41.43
23.72
20.48
21.15
27.47
24.84
25.7
25.47
24.23
24.23
Effective Tax Rate (%)
3.96
3.56
5.51
8.65
19.39
12.42
11.92
15.25
13.23
12.65
12.65
Profit Margin (%)
-60
-26
17
134
252
287
354
472
383
506
506
Working Capital
143
131
60
46
44
- -
- -
- -
- -
- -
- -
LT Debt
192
207
290
406
522
599
712
856
990
1,120
1,120
Total Equity
- -
6.38
9.22
11.67
18.78
14.44
15.83
18.09
12.18
9.44
9.44
Return on Invested Capital (%)
- -
6.07
10.49
17.81
32.98
20.47
20.69
21.43
16.46
26.28
26.28
Return on Capital (%)
- -
10.61
14.86
22.35
39.38
21.84
20.69
21.43
16.38
26.09
26.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
- -
12
Market Capitalization
1,289
1,246
968

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
624
- -
643
Cash, Cash Equivalents & STI
339
- -
418
Accounts Receivable, Net
176
- -
120
Inventories
53
- -
54
Total Current Liabilities
- -
- -
137
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.52%
13.14%
Free Cash Flow
- -
28.37%
-3.1%
Net Income, GAAP
- -
4.11%
-1.87%
Sales/Revenue/Turnover
- -
12.18%
2.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
229
259
240
223
951
2025
226
347
214
223
1,010
2026
260
287
293
196
1,037

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.01
3.97
2.78
- -
11.78
2025
2.06
6.99
0.47
1.34
10.86
2026
2.7
3.36
3.9
0.69
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
PolyPeptide Group AG (PPGN.SW)
Chongqing Taiji Industry(Group) Co.,Ltd (600129.SS)
Gujarat Themis Biosyn Ltd. (GUJTHEM.NS)
Alvotech (ALVOW)
Cohance Lifesciences Limited (COHANCE.BO)
Business
Par Drugs and Chemicals Limited Par Drugs and Chemicals Limited (PAR.NS) manufactures and exports active pharmaceutical ingredients and fine chemicals primarily for antacid and gastrointestinal applications from its facilities in Bhavnagar and Ankleshwar, Gujarat, India. Incorporated in 1999 and headquartered at 816 Nilamber Triumph, Gotri-Vasna Road, Vadodara, the company produces a diversified portfolio comprising 15 APIs including Magnesium Hydroxide, Sucralfate, Dried Aluminium Hydroxide Gel, Magaldrate, Magnesium Trisilicate, Almagate BP, Light Magnesium Carbonate, Colloidal Silicon Dioxide, Aluminium Magnesium Silicate, Magnesium Aluminometasilicate, Magnesium Aluminosilicate-USP, Magnesium Oxide Light and Heavy, Magnesium Aluminium Hydrate, Hydrotalcite, and Synthetic Aluminium Silicate; and 10 fine chemicals such as Precipitated Silica, Sodium Aluminium Silicate, Amorphous Aluminium Hydroxide, PARSIL-HT, PAR ADD OP, MagSil OF, FlowSil, Aluminium Hydroxide Magnesium Carbonate Co-Dried Gel, and Magnesium Aluminium Silicate-Hydrated for pharma and agro uses, with an annual capacity of 9,700 metric tons across four dedicated manufacturing blocks. As India's largest producer of Magnesium Hydroxide, Sucralfate, and Magnesium Trisilicate, it serves over 250 customers including Pfizer Ltd., Cipla Ltd., and United Phosphorus Ltd. through a network of more than 40 dealers and 13 agents, exporting to approximately 20 countries such as Germany, UK, UAE, Japan, South Korea, China, Bangladesh, Iran, Indonesia, and Nigeria. Recent developments include strategic expansion into high-potential markets like Japan, South Korea, and China to diversify revenue and mitigate regional risks; ongoing greenfield capacity enhancements; integration of automation and PLC technologies for operational efficiency; increased solar power capacity and freshwater reduction initiatives for sustainability; and robust FY24 financials with revenue of ₹9,588 lakhs, PBT up to ₹1,952 lakhs, PAT at ₹1,450 lakhs, and total equity rising to ₹8,563 lakhs, positioning the debt-free company for sustained growth.